{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:40:08Z","timestamp":1790746808299,"version":"4.1.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"6","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)\/protein kinase B pathway. This phase 2 study evaluated dosing, efficacy, and safety of add-on PI3K\u03b4 inhibitor parsaclisib for patients with primary or secondary myelofibrosis with suboptimal response to ruxolitinib. Eligible patients remained on a stable ruxolitinib dose and received add-on parsaclisib 10 or 20\u00a0mg, once daily for 8\u00a0weeks, and once weekly thereafter (daily-to-weekly dosing; n\u00a0= 32); or parsaclisib 5 or 20\u00a0mg, once daily for 8\u00a0weeks, then 5\u00a0mg once daily thereafter (all-daily dosing; n\u00a0=\u00a042). Proportion of patients achieving a \u226510% decrease in spleen volume at 12\u00a0weeks was 28% for daily-to-weekly dosing and 59.5% for all-daily dosing. Proportions of patients achieving \u226550% decrease at week 12 in Myelofibrosis Symptom Assessment Form and Myeloproliferative Neoplasms Symptom Assessment Form symptom scores were 14% and 18% for daily-to-weekly dosing, and 28% and 32% for all-daily dosing, respectively. Most common nonhematologic treatment-emergent adverse events were nausea (23%), diarrhea (22%), abdominal pain and fatigue (each 19%), and cough and dyspnea (each 18%). New-onset grade 3 and 4 thrombocytopenia were observed in 19% of patients, each dosed daily-to-weekly, and in 26% and 7% of patients dosed all-daily, respectively, managed with dose interruptions. Hemoglobin levels remained steady. The addition of parsaclisib to stable-dose ruxolitinib can reduce splenomegaly and improve symptoms, with manageable toxicity in patients with myelofibrosis with suboptimal response to ruxolitinib. This trial was registered at www.clinicaltrials.gov as #NCT02718300.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011620","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T22:12:20Z","timestamp":1706652740000},"page":"1515-1528","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5293-4620","authenticated-orcid":false,"given":"Abdulraheem","family":"Yacoub","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, University of Kansas Cancer Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Borate","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-7292","authenticated-orcid":false,"given":"Haris","family":"Ali","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kremyanskaya","sequence":"additional","affiliation":[{"name":"8Department of Hematology\/Oncology, Icahn School of Medicine at Mount Sinai, Manhattan, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott","family":"Winton","sequence":"additional","affiliation":[{"name":"9Department of Hematology Oncology, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"O\u2019Connell","sequence":"additional","affiliation":[{"name":"10Jane Anne Nohl Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7647-8922","authenticated-orcid":false,"given":"Swati","family":"Goel","sequence":"additional","affiliation":[{"name":"11Department of Medical Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-5400","authenticated-orcid":false,"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Schiller","sequence":"additional","affiliation":[{"name":"13Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McCloskey","sequence":"additional","affiliation":[{"name":"14Department of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2185-1504","authenticated-orcid":false,"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[{"name":"15Division of Hematology\/Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houston","family":"Holmes","sequence":"additional","affiliation":[{"name":"16Hematology and Medical Oncology, Texas Oncology\/Baylor-Sammons Cancer Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hager","sequence":"additional","affiliation":[{"name":"17C CARE, California Cancer Associates for Research & Excellence, Inc, Fresno, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Assad","sequence":"additional","affiliation":[{"name":"18Oncology Drug Development, Incyte Corporation, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Erickson-Viitanen","sequence":"additional","affiliation":[{"name":"19Clinical Development, Incyte Corporation, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhou","sequence":"additional","affiliation":[{"name":"20Biostatistics, Incyte Corporation, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"21Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"16","key":"2024032513152174600_bib1","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2024032513152174600_bib2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"2024032513152174600_bib3","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2024032513152174600_bib4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12185-022-03335-7","article-title":"Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives","volume":"115","author":"Loscocco","year":"2022","journal-title":"Int J Hematol"},{"key":"2024032513152174600_bib5","author":"JAKAFI (ruxolitinib)","year":"2023"},{"key":"2024032513152174600_bib6","author":"INREBIC (fedratinib)","year":"2021"},{"key":"2024032513152174600_bib7","author":"VONJO (pacritinib)","year":"2022"},{"key":"2024032513152174600_bib43","author":"OJJAARA (momelotinib)","year":"2023"},{"issue":"15","key":"2024032513152174600_bib8","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2024032513152174600_bib9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024032513152174600_bib10","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"2024032513152174600_bib11","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024032513152174600_bib12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"2024032513152174600_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2141.2010.08249.x","article-title":"JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation","volume":"150","author":"Oku","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"2024032513152174600_bib14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2141.2009.07870.x","article-title":"Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms","volume":"147","author":"Grimwade","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"2024032513152174600_bib15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000450956","article-title":"Molecular pathogenesis and clinical significance of driver mutations in primary myelofibrosis: a review","volume":"25","author":"Alshemmari","year":"2016","journal-title":"Med Princ Pract"},{"issue":"57","key":"2024032513152174600_bib16","doi-asserted-by":"crossref","first-page":"96710","DOI":"10.18632\/oncotarget.18073","article-title":"Inhibitors of the PI3K\/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A\/CIP2A axis","volume":"8","author":"Bartalucci","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"2024032513152174600_bib17","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/jcmm.12162","article-title":"Co-targeting the PI3K\/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms","volume":"17","author":"Bartalucci","year":"2013","journal-title":"J\u00a0Cell Mol Med"},{"issue":"8","key":"2024032513152174600_bib18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/14737140.2022.2093192","article-title":"Targeting the PI3K pathway in myeloproliferative neoplasms","volume":"22","author":"Gerds","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"issue":"21","key":"2024032513152174600_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3835.3835","article-title":"Inhibitors of PI3K\/Akt and\/or mTOR inhibit the growth of cells of myeloproliferative neoplasms and synergize with JAK2 inhibitor and interferon [abstract]","volume":"118","author":"Vannucchi","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2024032513152174600_bib20","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/leu.2013.167","article-title":"AKT is a therapeutic target in myeloproliferative neoplasms","volume":"27","author":"Khan","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"2024032513152174600_bib21","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1021\/acsmedchemlett.9b00334","article-title":"INCB050465 (parsaclisib), a novel next-generation inhibitor of phosphoinositide 3-kinase delta (PI3K\u03b4)","volume":"10","author":"Yue","year":"2019","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"2024032513152174600_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2020.08.022","article-title":"Can next-generation PI3K inhibitors unlock the full potential of the class in patients with B-cell lymphoma?","volume":"21","author":"Phillips","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2024032513152174600_bib23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2024032513152174600_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"issue":"S1","key":"2024032513152174600_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.HS9.0000560980.98764.a5","article-title":"PF674 outcome of patients with myelofibrosis after ruxolitinib discontinuation: role of disease status and treatment strategies in 218 patients [abstract]","volume":"3","author":"Palandri","year":"2019","journal-title":"HemaSphere"},{"issue":"S1","key":"2024032513152174600_bib26","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/01.HS9.0000564104.83392.dc","article-title":"PS1460 long-term follow up of jak inhibitor (JAKi) treated patients with myelofibrosis: impact of molecular enhanced integrated scoring systems and type of JAKi therapy failure on survival","volume":"3","author":"McNamara","year":"2019","journal-title":"HemaSphere"},{"issue":"16","key":"2024032513152174600_bib27","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Forero-Torres","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2024032513152174600_bib28","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"issue":"2","key":"2024032513152174600_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"2024032513152174600_bib30","author":"National Institute of Mental Health (US)","year":"2020"},{"issue":"8","key":"2024032513152174600_bib31","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2024032513152174600_bib32","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00280-016-3012-z","article-title":"Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib","volume":"77","author":"Bryan","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024032513152174600_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1756-8722-5-43","article-title":"Splenomegaly in myelofibrosis\u2014new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors","volume":"5","author":"Randhawa","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"issue":"9","key":"2024032513152174600_bib34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024032513152174600_bib35","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"10373","key":"2024032513152174600_bib36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"issue":"15","key":"2024032513152174600_bib37","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2024032513152174600_bib38","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis","volume":"39","author":"Mascarenhas","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024032513152174600_bib39","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A\u00a0pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"2024032513152174600_bib40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.clml.2017.05.015","article-title":"Practical measures of clinical benefit with ruxolitinib therapy: an exploratory analysis of COMFORT-I","volume":"17","author":"Miller","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2024032513152174600_bib41","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1097\/HS9.0000000000000562","article-title":"Fedratinib improves myelofibrosis-related symptoms and health-related quality of life in patients with myelofibrosis previously treated with ruxolitinib: patient-reported outcomes from the phase II JAKARTA2 trial","volume":"5","author":"Harrison","year":"2021","journal-title":"HemaSphere"},{"issue":"9","key":"2024032513152174600_bib42","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ajh.24442","article-title":"Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients","volume":"91","author":"Guglielmelli","year":"2016","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1515\/2218941\/blooda_adv-2023-011620-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1515\/2218941\/blooda_adv-2023-011620-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T13:15:53Z","timestamp":1711372553000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/6\/1515\/514765\/Phase-2-study-of-add-on-parsaclisib-for-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011620","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}